<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579861</url>
  </required_header>
  <id_info>
    <org_study_id>5009</org_study_id>
    <nct_id>NCT04579861</nct_id>
  </id_info>
  <brief_title>GO SOAR1: Post-Operative Morbidity and Mortality Following Gynaecological Oncology Surgery</brief_title>
  <acronym>GO SOAR1</acronym>
  <official_title>Determining Post-operative Morbidity and Mortality Following Gynaecological Oncology Surgery: a Multicentre, International, Prospective Cohort Study Led by the Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faiza Gaba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Hertfordshire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Grampian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Network of Young Gynae Oncologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NHS Grampian</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Global Gynaecological Oncology Surgical Outcomes Collaborative (GO SOAR) will develop a&#xD;
      network of gynaecological oncology surgeons, surgical departments and other interested&#xD;
      parties that will have the long-term ability to collaborate on outcome studies. The aims of&#xD;
      the Collaborative are to:&#xD;
&#xD;
        1. Set the research agenda through research prioritisation in gynaecological oncology&#xD;
           surgical outcomes.&#xD;
&#xD;
        2. Gather high quality data via a centralised database accessible to all sites that perform&#xD;
           gynaecological oncology surgery.&#xD;
&#xD;
        3. Build sustainable international research by producing protocols/guidelines.&#xD;
&#xD;
        4. Train the researchers and leaders of tomorrow by providing open access to all GO SOAR&#xD;
           training materials.&#xD;
&#xD;
      The Collaborative will lead to several studies.&#xD;
&#xD;
      The first GO SOAR collaborative study (GO SOAR1) will evaluate international variation of&#xD;
      post-operative morbidity and mortality following gynaecological oncology surgery between&#xD;
      country groups defined by the human development index (HDI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study hypothesis&#xD;
&#xD;
      There is no variation in post-operative morbidity and mortality rates following&#xD;
      gynaecological oncology surgery between HDI country groups.&#xD;
&#xD;
      Regulatory approval&#xD;
&#xD;
      Quality Improvement &amp; Assurance Team, Research and Development NHS Grampian (Project ID&#xD;
      5009).&#xD;
&#xD;
      Study design&#xD;
&#xD;
      International, multi-centre, prospective cohort study.&#xD;
&#xD;
      Primary objectives&#xD;
&#xD;
      1. To evaluate international variation of post-operative morbidity and mortality following&#xD;
      gynaecological oncology surgery between country groups defined by HDI.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        1. To evaluate international variation between HDI country groups of intra-operative&#xD;
           morbidity and mortality following gynaecological oncology surgery.&#xD;
&#xD;
        2. To evaluate international variation between HDI country groups of histological clearance&#xD;
           rates of gynaecological malignancies.&#xD;
&#xD;
        3. To establish an international gynaecological oncology collaborative and surgical&#xD;
           outcomes database.&#xD;
&#xD;
        4. To identify modifiable surgical processes.&#xD;
&#xD;
        5. To establish best practices and standards for gynaecological oncology surgery.&#xD;
&#xD;
        6. To champion promotion of quality improvement and research and gynaecological oncology&#xD;
           surgical training.&#xD;
&#xD;
      Interventions&#xD;
&#xD;
      Patient data will be collected over a consecutive thirty day period through gynaecological&#xD;
      oncology multidisciplinary teams/tumour boards and clinics across different human development&#xD;
      index country groups. Additional data entry (beyond thirty days) is encouraged and may take&#xD;
      place at the discretion of the participating site. All patients are followed up as per local&#xD;
      protocols for thirty days post-operatively to identify post-surgical morbidity/mortality. For&#xD;
      each patient, data will be captured on demographic variables, centre/unit/hospital site, FIGO&#xD;
      staging, surgical modality, intra-operative morbidity/mortality, 30 day morbidity/mortality&#xD;
      following surgery, tumour resectability, access to diagnostic endoscopy/hysteroscopy,&#xD;
      histopathology/radiological imaging/laboratories/critical care facilities, multidisciplinary&#xD;
      team/tumour board meetings, chemotherapy, radiotherapy seniority and training of lead&#xD;
      surgeon. All data is collected on a customised, secure, password protected central REDCap&#xD;
      database.&#xD;
&#xD;
      Follow up&#xD;
&#xD;
      All investigators are required to monitor patients for thirty days post-operatively to&#xD;
      identify complications. Most of these events are expected to occur during the individual's&#xD;
      inpatient stay. Centres must be proactive in identifying post-operative events (or an absence&#xD;
      of them), within the limits of normal follow up. Local arrangements may include:&#xD;
&#xD;
        1. Daily review of patient status and notes before discharge to identify inpatient&#xD;
           complications.&#xD;
&#xD;
        2. Reviewing the patient status at a post-surgery follow up appointment in an outpatient&#xD;
           clinic or via telephone (if this is normal practice).&#xD;
&#xD;
        3. Checking hospital records (electronic/paper) or handover lists for&#xD;
           re-attendances/re-admissions.&#xD;
&#xD;
        4. Checking for Emergency Department re-attendances.&#xD;
&#xD;
        5. Contacting general/family practitioners to enquire about complications managed in&#xD;
           primary care.&#xD;
&#xD;
      International Steering Committee&#xD;
&#xD;
      An international steering committee will oversee the study. The committee will monitor and&#xD;
      supervise progress and adherence to protocol. The committee will review at regular intervals&#xD;
      relevant information from other sources, e.g. other audits/studies. It will ensure that the&#xD;
      study is conducted to a high standard in line with Guidelines for Good Clinical Practice. The&#xD;
      committee will meet every six months though more frequent meetings may be called if&#xD;
      necessary. Meetings will be called for by the chief investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative surgical morbidity</measure>
    <time_frame>30 days</time_frame>
    <description>Post-operative surgical morbidity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-operative surgical mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Post-operative surgical mortality</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Gynecologic Cancer</condition>
  <condition>Surgery</condition>
  <condition>Surgery--Complications</condition>
  <arm_group>
    <arm_group_label>High human development</arm_group_label>
    <description>Countries classified as very high and high human development as per the United Nations development programme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low and medium human development</arm_group_label>
    <description>Countries classified as low and medium human development as per the United Nations development programme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective data collection following gynaecological oncology surgery</intervention_name>
    <description>Prospective data collection and entry on database following gynaecological oncology surgery</description>
    <arm_group_label>High human development</arm_group_label>
    <arm_group_label>Low and medium human development</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women &gt;18 years undergoing gynaecological oncology surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged &gt;18 years undergoing curative, curative attempted but then abandoned (i.e.&#xD;
             open/close laparotomy) or palliative surgery for primary tubo-ovarian/peritoneal,&#xD;
             endometrial, cervical, vulval, vaginal, gestational trophoblastic malignancies.&#xD;
&#xD;
          2. Surgery for recurrent primary tubo-ovarian/peritoneal, endometrial, cervical, vulval,&#xD;
             vaginal, gestational trophoblastic malignancies.&#xD;
&#xD;
          3. Open, minimal access (laparoscopic/robotic), minimal access converted to open or&#xD;
             vaginal surgeries for tubo-ovarian/peritoneal, endometrial, cervical, vulval, vagina,&#xD;
             gestational trophoblastic malignancies.&#xD;
&#xD;
          4. Elective and emergency surgeries.&#xD;
&#xD;
          5. Surgeries where pre-operative pathology thought to be benign but malignancy confirmed&#xD;
             on histopathology post-operatively.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Surgeries where pre-operative pathology thought to be malignant but benign disease&#xD;
             confirmed on histopathology post-operatively.&#xD;
&#xD;
          2. Non gynaecological disease as the primary malignancy.&#xD;
&#xD;
          3. Diagnostic procedures (e.g. staging laparoscopy, image guided biopsy).&#xD;
&#xD;
          4. Any procedure not requiring a skin incision under general/regional anaesthesia (e.g.&#xD;
             chemotherapy, radiotherapy, hysteroscopy).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faiza Gaba</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Grampian</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faiza Gaba</last_name>
    <phone>+441224 552604</phone>
    <email>faiza.gaba@nhs.scot</email>
  </overall_contact>
  <location>
    <facility>
      <name>NHS Grampian</name>
      <address>
        <city>Aberdeen</city>
        <state>County (optional)</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faiza Gaba</last_name>
      <email>faiza.gaba@nhs.scot</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>March 6, 2021</last_update_submitted>
  <last_update_submitted_qc>March 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>NHS Grampian</investigator_affiliation>
    <investigator_full_name>Faiza Gaba</investigator_full_name>
    <investigator_title>Collaborative Lead &amp; Chief Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

